November 18, 2022Early signal of activity from a phase 2 study of ST101, a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ), in recurrent glioblastoma (GBM)November 10, 2022ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responsesOctober 27, 2022Efficacy signals, long-term exposure and safety data from a phase 1-2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients with refractory solid tumorsJune 3, 2022Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumorsApril 11, 2022Characterizing the PK/PD relationship of C/EBPβ antagonist peptide ST101 in a mouse orthotopic breast cancer modelApril 11, 2022β-catenin antagonist peptide, ST316, attenuates Wnt-dependent oncogenic activitySeptember 16, 2021Efficacy, safety, pharmacokinetic and pharmacodynamic data from phase 1 dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with advanced and metastatic solid tumorsApril 9, 2021β-catenin antagonist peptide attenuates Wnt-dependent oncogenic activityApril 9, 2021C/EBPβ antagonist peptide, ST101, as a potential therapeutic approach in breast cancerJune 22, 2020β-catenin antagonist peptide attenuates oncogenic gene transactivation and promotes antitumor activity in breast cancer modelsJune 22, 2020C/EBPβ antagonist peptide, ST101, attenuates oncogenic gene transactivation in cancer cells to drive antitumor activityApril 1, 2019Cell penetrating peptide, ST101, disrupts ATF5 regulation of anti-apoptotic Bcl-2 family proteins, resulting in induction of cancer cell death in vitro and tumor growth inhibition/regression in vivo
